Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain cancer vaccine targets survivin protein to boost immune attack

NCT ID NCT07715097

Not yet recruiting Disease control Sponsor: Beijing Tricision Biotherapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This phase II trial tests whether a personalized dendritic cell vaccine targeting the Survivin protein can improve survival in people with newly diagnosed glioblastoma, an aggressive brain cancer. Participants receive the vaccine alongside standard chemotherapy after surgery. The study aims to see if this immune-boosting approach helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a personalized dendritic cell vaccine that targets the Survivin protein, given alongside standard chemotherapy
What this could lead to
If successful, this approach could extend survival for people with glioblastoma, a brain cancer with few effective treatments.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. The vaccine may cause immune-related side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma susceptibility 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.